Genes, Dreams, and Dollar Schemes

Gene therapy's comeback kid is massively undervalued with 65% upside potential. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

📱 Do You Use an iPhone? If So... Read This NOW You may have noticed that Apple introduced new email categories: Primary, Transactions, Updates, and Promotions. And many subscribers are finding that their important alerts are going into the wrong category. Don't let Apple sort your emails for you! Click here to ensure you never miss an important update from us. BROUGHT TO YOU BY MANWARD PRESS Dealmaker's Diary: The Rare Disease Fighter Trading at Bargain Prices SPONSORED "April 2 is a liberating day for our country." President Trump says, "April 2 is a liberating day for our country." And that may be true in the long run but, for many unprepared investors, the market's reaction to his April 2 tariffs could be rough. In fact, the president has repeatedly referred to April 2 as "the big one." And that's why it's imperative that investors lock in THIS 200% contractually obligated return over the next four years. Learn more here...   Alpesh Patel Quantitative Investing Specialist Remember when gene therapy was the hot topic? How did we forget that we could literally edit human DNA? Well, their loss is our gain. The stock I want to show you today isn't your average biotech. It's a $5 billion powerhouse tackling rare diseases. SPONSORED The 'Law and Order' Portfolio: Trump Stocks Set to Surge Source: Wikimedia Commons These defense and security stocks could EXPLODE during Trump's Second Stockwave... Thanks to a special plan outlined in Trump's "Document 20" that aims to secure our border and make America safer. Click here to see details on what stocks could soar.   Unlike most biotech companies, it generates positive cash flow. And the best part - it's incredibly cheap. You're paying just $25 for every $1 in future profits for a biotech company that leverages AI. Get all the details on the company - including the ticker - in today's Dealmaker's Diary. Click here or on the image below to watch. Happy hunting, Alpesh WATCH THE VIDEO (WITH TRANSCRIPT) SPONSORED "A juggernaut... to rival the likes of Google and Netflix in power and value" Is this most valuable AI stock in the world?   Want more content like this? YES NO

Alpesh Patel Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.

You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Total Wealth. © 2025 Manward Press, LLC | All Rights Reserved

Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.